IDH1 and acute myeloid leukemia: Ivosidenib has also been evaluated in a phase 3 trial in combination with AZA versus AZA monotherapy in patients with newly diagnosed IDH-1-mutated AML; the median OS was 24 months in the combination AZA/ivosidenib group, versus 7.9 months in the AZA/placebo group [92].